Triple negative breast cancer (TNBC) causes a significant challenge in oncology due to its aggressive nature and limited treatment options. This study introduces a promising strategy to enhance therapeutic effectiveness against TNBC by developing a dual-functioning 7-amino-6Hanthra[9,1-cd] isothiazol-6-one (AAT) encapsulated Casein nanosystem (CAAT NPs). This innovative approach serves both as a live cell staining technique and as a means to augment therapeutic outcomes in highly metastatic TNBC. AAT, chosen for its dual role as a fluorescence marker for live cells and its inherent anticancer properties, undergoes fluorescence quenching upon inducing cancer cell death. The Casein nanosystem ensures efficient dye encapsulation, providing stability and controlled release. Physicochemical analysis validates successful encapsulation, yielding a desirable size distribution of CAAT NPs. Cellular uptake studies demonstrate effective internalization in 4T1 cells with minimal cytotoxicity in healthy cell lines and organisms. Subsequent investigations revealed subcellular localization, altered mitochondrial membrane potential, nucleus breakage, antimigration activity, and growth suppression in 4T1 cells. Increased expression of γH2AX, indicating DNA damage, further underscores the therapeutic potential. In a 3-D model of 4T1 cells, CAAT NPs exhibit significant therapeutic efficacy, suggesting a promising option for safe and efficient TNBC treatment.